Delap Wealth Advisory LLC Acquires Shares of 14,234 Organogenesis Holdings Inc. (NASDAQ:ORGO)

Delap Wealth Advisory LLC purchased a new position in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 14,234 shares of the company’s stock, valued at approximately $40,000.

Other large investors also recently modified their holdings of the company. Victory Capital Management Inc. purchased a new stake in shares of Organogenesis during the 4th quarter worth approximately $43,000. Pallas Capital Advisors LLC purchased a new stake in shares of Organogenesis during the 2nd quarter worth approximately $38,000. Allspring Global Investments Holdings LLC increased its stake in shares of Organogenesis by 4,989.9% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock worth $44,000 after purchasing an additional 15,369 shares during the last quarter. CWM LLC increased its stake in shares of Organogenesis by 301.8% during the 2nd quarter. CWM LLC now owns 25,617 shares of the company’s stock worth $72,000 after purchasing an additional 19,242 shares during the last quarter. Finally, Caxton Associates LP purchased a new stake in shares of Organogenesis during the 1st quarter worth approximately $88,000. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Organogenesis Stock Down 3.4 %

Organogenesis stock opened at $2.83 on Friday. Organogenesis Holdings Inc. has a 1-year low of $1.96 and a 1-year high of $4.70. The firm has a market capitalization of $375.17 million, a price-to-earnings ratio of 70.77 and a beta of 1.62. The company has a current ratio of 2.73, a quick ratio of 2.42 and a debt-to-equity ratio of 0.22. The firm has a 50 day simple moving average of $2.80 and a 200 day simple moving average of $2.75.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.11). Organogenesis had a negative net margin of 3.69% and a negative return on equity of 6.03%. The business had revenue of $130.23 million during the quarter, compared to analysts’ expectations of $122.48 million. On average, analysts predict that Organogenesis Holdings Inc. will post -0.19 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Lake Street Capital began coverage on shares of Organogenesis in a research note on Friday, June 28th. They set a “buy” rating and a $5.00 price target for the company.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.